Avilar Therapeutics

Extracellular Targeted Protein Degradation

Additional undisclosed programs RD neurological conditions, undisclosed

Avilar Therapeutics is developing methods to degrade extracellular proteins. More than 35% of human proteins are located outside the cell and many have a clearly defined role in the pathogenesis of human diseases. Avilar is developing novel degraders of extracellular proteins as future medicines for the treatment of multiple serious diseases. Avilar’s new class of degraders harness ASGPR receptors that play a key role in the natural process through which endogenous proteins are internalized and degraded by hepatocytes. The degraders are bifunctional molecules that bind both ASGPR and a disease-causing extracellular protein. Using an X-ray structure guided approach, Avilar is discovering a library of bifunctional, high affinity molecules to target a wide range of extracellular proteins.